Acta Neurologica Belgica

, Volume 119, Issue 3, pp 379–384 | Cite as

Autosomal-recessive iron deficiency anemia, dystonia and hypermanganesemia caused by new variant mutation of the manganese transporter gene SLC39A14

  • Adel ZeglamEmail author
  • Abdusalam Abugrara
  • Mariam Kabuka
Original Article


This inborn error of manganese metabolism has only recently been identified. A total of 28 affected individuals from ten families are known worldwide. Mutations in SLC39A14, encoding a Mn uptake transporter, have recently been recognized to cause excessive Mn concentrations in the blood which is believed to be neurotoxic and lead to a parkinsonian-like movement disorder caused by accumulation of Mn in the basal ganglia. We are reporting a new variant of SLC39A14 gene mutation (OMIM 608736 8p21.3) that has never been described in the literature so far. The index case is a 3-year-old female who was born at 30 weeks’ gestation by emergency lower segment caesarean section, the second of twins, weighing 1.4 kg. Parents have a consanguineous marriage (first cousins) and have four healthy male children. She presented at 30 months of age with history of unsteady gait of 4 months duration and is progressively worsening. She became stiff and has lost all of her locomotor skills. Apart from low serum iron and iron deficiency anemia, her initial work up was unremarkable. T1-weighted MRI brain showed bilateral hyperintense signal in basal ganglia, mid-brain and pontine tegmentum giving rise to the characteristic eye-of-the-tiger sign. Genetic DNA evaluation (Whole Exome Sequencing WES) identified the homozygous missense variant c.1136.T in exon 7 of SLC39A14 gene which is associated with hypermanganesemia. Whole blood Mn was markedly raised at 150 nmol/L (8 mg/L) (normal 10 nmol/L, 0.7 mg/Bioscientia). This young girl has just started treatment with intravenous disodium calcium edetate and oral iron.


SLC39A14 Tripoli Libya Dystonia Hypermanganesemia Eye of tiger 





The solute carrier


Hypermanganesemia with dystonia type 2


Pantothenate kinase-associated neurodegeneration


Author contributions

AZ: Prof. Zeglam conceptualized and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted. AA: Dr. Abugrara read, wrote and commented on the brain MRI finding. Approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.


The authors have no financial relationships relevant to this article to disclose.

Compliance with ethical standards

Conflict of interest

We have no conflicts of interest to disclose.

Ethical standards

All procedures performed were in accordance with the ethical standards of the hospital.

Informed consent

Informed consent was obtained from all individual participants included in this case report.


  1. 1.
    Chen P, Parmalee N, Aschner M (2014) Genetic factors and manganese-induced neurotoxicity. Front Genet 5:265PubMedPubMedCentralGoogle Scholar
  2. 2.
    Santos D et al (2012) Manganese alters rat brain amino acids levels. Biol Trace Elem Res 150:337–341CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    EriksonK M, Thompson K, Aschner J, Aschner M (2007) Manganese neurotoxicity: a focus on the neonate. Pharmacol Ther 113:369–377CrossRefGoogle Scholar
  4. 4.
    Williams M, Todd GD, Roney N et al (2012) Toxicological profile for manganese. Atlanta (GA): agency for Toxic Substances and Disease Registry (US)Google Scholar
  5. 5.
    Agency for Toxic Substances and Disease Registry (2000) Toxicological profile for manganese (update). Agency for Toxic Substances and Disease Registry. A-3 to A-5, AtlantaGoogle Scholar
  6. 6.
    Fanh S, Marsden CD, Caine DB (1988) Dystonia 2. Proceedings of the Second International Symposium on Torsion Dystonia. Harriman, New York (1986). Adv Neurol 50:1–705Google Scholar
  7. 7.
    DeFazio G, Berardelli A, Hallett M (2007) Do primary adult-onset focal dystonias share etiological factors? Brain 130:1183–1193CrossRefPubMedGoogle Scholar
  8. 8.
    Breakefield XO, Blood AJ, Li Y et al (2008) The pathophysiological basis of dystonias. Nature Rev Neurosci 9:222–234CrossRefGoogle Scholar
  9. 9.
    Geyer HL, Bressman SB (2006) The diagnosis of dystonia. Lancet Neurol 5:780–790CrossRefPubMedGoogle Scholar
  10. 10.
    Taylor KM, Morgan HE, Johnson A, Nicholson RI (2005) Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett 579:427–432CrossRefPubMedGoogle Scholar
  11. 11.
    Tominaga K et al (2005) SLC39A14, a LZT protein, is induced in adipogenesis and transports zinc. FEBS J 272:1590–1599CrossRefPubMedGoogle Scholar
  12. 12.
    Roth JA (2014) Correlation between the biochemical pathways altered by mutated Parkinson-related genes and chronic exposure to manganese. Neurotoxicology 44C:314–325CrossRefGoogle Scholar
  13. 13.
    Marti-Sanchez L, Ortigoza-Escobar JD, Dueñas P et al (2018) Hypermanganesemia due to mutations in SLC39A14: further insights into Mn deposition in the central nervous system. Orphanet J Rare Dis. (ISSN: 1750-1172) CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Xin Y, Gao H, Fudi W et al (2017) Manganese transporter Slc39a14 deficiency revealed its key role in maintaining manganese homeostasis in mice. Cell Disc. CrossRefGoogle Scholar
  15. 15.
    Zogzas CE, Mukhopadhyay S (2017) Inherited disorders of manganese metabolism. In: Aschner M, Costa L (eds) Neurotoxicity of metals. Advances in Neurobiology, vol 18. Springer, Cham. CrossRefGoogle Scholar
  16. 16.
    Nebert DW et al (2012) ZIP14 and ZIP8 zinc/bicarbonate symporters in Xenopus oocytes: characterization of metal uptake and inhibition. Metallomics 4:1218–1225CrossRefPubMedGoogle Scholar
  17. 17.
    Zhao N, Gao J, Enns CA, Knutson M (2010) D. ZRT/IRT–like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem 285:32141–32150CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Perland E, Fredriksson R (2017) Classification systems of secondary active transporters. Trends Pharmacol Sci 38(3):305–315. (ISSN 1873-3735. PMID 27939446) CrossRefPubMedGoogle Scholar
  19. 19.
    Tuschl K, Meyer E, Valdivia LE, Zhao N, Dadswell C, Abdul-Sada A, Wilson SW (2016) Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood onset parkinsonism–dystonia. Nat Commun 7:11601. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Juneja M, Shamim U, Joshi A et al (2018) A novel mutation in SLC39A14 causing hypermanganesemia associated with infantile onset dystonia. Gene Med. CrossRefGoogle Scholar
  21. 21.
    Rodan LH, Hauptman M, D’Gama AM, Qualls AE, Cao S, Tuschl K, Agrawal PB, Al-Jasmi F (2018) Novel founder intronic variant in SLC39A14 in two families causing manganism and potential treatment strategies. Mol Genet Metabol. 124(2):161–167. CrossRefGoogle Scholar
  22. 22.
    Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T (2005) The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden–Spatz syndrome. Neuropediatrics 36:221–222CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2018

Authors and Affiliations

  • Adel Zeglam
    • 1
    Email author
  • Abdusalam Abugrara
    • 2
  • Mariam Kabuka
    • 1
  1. 1.Department of Pediatrics, Tripoli Medical Centre, University Teaching Hospital, Faculty of MedicineTripoli UniversityTripoliLibya
  2. 2.Department of Diagnostic RadiologyTripoli Medical CentreTripoliLibya

Personalised recommendations